US 2026/0224676 A1 · TAU AND AMYLOID BETA PEPTIDE IMMUNOGEN COMPOSITIONS AND RELATED METHODS

Abstract

The present disclosure is directed to improved peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to improved peptide immunogen constructs targeting portions of the amyloid beta protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions and kits containing the peptide immunogen constructs, in particular compositions and kits comprising combinations of various peptide immunogen constructs. Methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs, are also provided herein. In some aspects, the disclosure is directed to compositions comprising peptide immunogen constructs based on portions of the Tau protein and peptide immunogen constructs based on portions of the amyloid beta protein, and use of these peptide immunogen constructs and compositions in therapeutic methods.

Claims59

Dependent claims

A composition or a kit comprising a first Tau peptide immunogen construct comprising a first Tau B cell epitope comprising or consisting of 6 to about 40 amino acid residues from the full-length Tau protein of SEQ ID NO:

60;
and
(i) a second Tau peptide immunogen construct comprising a second Tau B cell epitope comprising or consisting of 6 to about 40 amino acid residues from the full-length Tau protein of SEQ ID NO:
60, wherein the second B cell epitope is not the same as the first B cell epitope, and/or
(ii) an amyloid beta (Aβ) peptide immunogen construct comprising an amyloid beta B cell epitope comprising or consisting of 6 to about 42 amino acid residues from the full-length amyloid beta protein of SEQ ID NO:
68.

3 more elements

A method of preventing, inhibiting, reducing the severity of, delaying, or treating a tauopathy in a subject, the method comprising administering to the subject:

a first Tau peptide immunogen construct comprising a first Tau B cell epitope comprising or consisting of 6 to about 40 amino acid residues from the full-length Tau protein of SEQ ID NO:
60;
and
(i) a second Tau peptide immunogen construct comprising a second Tau B cell epitope comprising or consisting of 6 to about 40 amino acid residues from the full-length Tau protein of SEQ ID NO:
60, wherein the second B cell epitope is not the same as the first B cell epitope, and/or
(ii) an amyloid beta (Aβ) peptide immunogen construct comprising an amyloid beta B cell epitope comprising or consisting of 6 to about 42 amino acid residues from the full-length amyloid beta protein of SEQ ID NO:
68;
and
wherein the first Tau peptide immunogen construct, and the second Tau peptide immunogen construct and/or the amyloid beta peptide immunogen construct, are comprised within separate compositions, which are administered separately.

6 more elements

Dependencies are inferred from the claim text.

Tau and amyloid beta peptide immunogen compositions and related methods

Life of this patent

Tau and amyloid beta peptide immunogen compositions and related methods

Life of this patent

Abstract

Claims59